某 M1/M4 受体激动剂在中期试验中显著改善精神分裂症症状
M1/M4 Agonist Relieved Schizophrenia Symptoms in Mid-Stage Trial
ML-007C-MA 在中期试验中显著改善精神分裂症症状,达到主要和次要终点,且安全性良好。
研究显示某 M1/M4 受体激动剂在中期试验中显著改善精神分裂症症状,为该类药物提供了新证据。
— Twice-daily dose hit primary and secondary endpoints
November 9, 2026 • 3 min read
ML-007C-MA, an investigational muscarinic M1/M4 receptor agonist that combines betovumeline and fesoterodine fumarate, significantly improved schizophrenia symptoms in adults who had an acute exacerbation of psychosis, data from the randomized phase II ZEPHYR trial showed.
Those receiving a twice-daily ML-007C-MA dose of 210 mg betovumeline/3 mg fesoterodine fumarate (210/3 mg BID) achieved a statistically significant improvement in Positive and Negative Syndrome Scale (PANSS) total score compared with placebo at week 5 (least squares mean difference -4.5 points, P=0.015), reported Kimberly Thompson, PhD, of MapLight Therapeutics, and colleagues.
A once-daily dose of 330 mg betovumeline/6 mg fesoterodine, which delivered lower overall daily exposure, demonstrated numerical improvement over placebo on the primary endpoint but did not achieve statistical significance (-2.8 points, P=0.110).
The findings were presented at the Neuroscience Education Institute (NEI) Fall Congress in Colorado Springs, Colorado.
The 210/3 mg BID dose also met several other key secondary and prespecified endpoints at week 5:
- Clinical Global Impressions-Severity (CGI-S): least squares mean difference versus placebo of -0.38 points (P=0.002)
- PANSS Marder positive factor score: least squares mean difference of -1.6 points (P=0.012)
- PANSS positive subscale: least squares mean difference of -2.3 points (P<0.001)
- Cogstate cognitive composite score (in participants with baseline impairment): least squares mean difference of +0.44 points (P=0.041)
Additionally, participants on the 210/3 mg BID regimen were 2.4 times more likely to achieve a ≥30% reduction in PANSS total score (P=0.021) and 2.8 times more likely to be deemed ready for discharge from an inpatient psychiatric setting by week 5 (P=0.002).
"Despite recent advances in schizophrenia treatment, patients and clinicians continue to need therapies that pair meaningful symptom control with a tolerability profile patients can sustain over time," co-author John Kane, MD, of the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in New York, said in a company statement.
"The ZEPHYR results are notable on both fronts: a statistically significant improvement on the primary endpoint and cognitive performance, alongside a meaningfully differentiated safety profile that matters most for the management of patients over time," he noted.
ML-007C-MA is an oral, extended-release, fixed-dose combination pairing the investigational M1/M4 agonist betovumeline (ML-007) with fesoterodine fumarate, a peripherally acting muscarinic antagonist. The co-formulation is engineered to sustain central M1/M4 activation in the brain while blocking peripheral cholinergic side effects like nausea, hypersalivation, and gastrointestinal (GI) distress.
By engaging muscarinic rather than dopamine receptors, this mechanism may offer an alternative pathway for patients who are refractory to or intolerant of traditional dopamine-blocking antipsychotics. Xanomeline and trospium chloride (Cobenfy) was the first M1/M4 receptor agonist approved in September 2024, establishing the first novel mechanistic class for schizophrenia in more than three decades.
The 25-site, double-blind trial enrolled 307 participants ages 18 to 64 years with a schizophrenia diagnosis confirmed by the Mini-International Neuropsychiatric Interview. Eligibility criteria required a baseline PANSS total score between 80 and 120, a score of 4 or higher on two or more positive symptom items, a CGI-S score of 4 or higher, and no concurrent antipsychotic therapy.
In the 210/3 mg BID arm, the mean age was 42 years, 70% were male, and 74% identified as Black. Disease severity at baseline was high, reflected by a mean PANSS total score of 96 (on a scale of 30 to 210) and a mean CGI-S score of 5 (on a scale of 1 to 7).
ML-007C-MA was generally well tolerated, with the majority of treatment-emergent adverse events categorized as mild or moderate. No serious or drug-related severe adverse events occurred, and investigators noted an absence of urinary retention, metabolic dysregulation, hepatic liability, or extrapyramidal movement-related signals.
Approximately 7% of participants discontinued treatment due to adverse events (2% attributable to GI issues) compared with 1% in the placebo group.
"No fasting requirement and a one-dose titration support a tolerability profile that is expected to translate into real-world adherence," the researchers noted.
MapLight announced plans to meet with the FDA to discuss phase III trial designs.
来源:MedPage Today · medpagetoday.com